Main > ONCOLOGY (**) > Solid Tumors. *** > UK. G. Advanced or Recurrent dMMR

---

UK. G. Advanced or Recurrent dMMR's subsections
(*) USA Approval Date: 2021. 08.17
Company
Generic Name: Dostarlimab
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 2
Patent>UpDate: 2021. 08.17.
Patent>UpDate: 2021. 08.17.
PR Web-Site
TradeMark
Treat.: PD-1 Blocking MAb

UK. G. Advanced or Recurrent dMMR's products
This section has no products